Bar-Shavit R, Maoz M, Ginzburg Y, Vlodavsky I
Department of Oncology, Hadassah-University Hospital, Jerusalem, Israel.
J Cell Biochem. 1996 May;61(2):278-91. doi: 10.1002/(SICI)1097-4644(19960501)61:2%3C278::AID-JCB11%3E3.0.CO;2-I.
We have previously demonstrated that thrombin possesses an active yet cryptic Arg-Gly-Asp (RGD) site which upon exposure induces endothelial cell (EC) adhesion via alpha nu beta 3 integrin [Bar-Shavit et al. (1991): J Cell Biol 112:335]. This was achieved in the presence of cell surface-associated heparan sulfate proteoglycans (HSPG) and exceedingly low concentrations of plasmin [Bar-Shavit et al. (1993): J Cell Biol 123:1279]. A portion of the cell surface-associated HSPG (glypican) is anchored via a covalently linked glycosyl-phosphatidylinositol (PI) residue, which can be released by treatment with glycosyl-PI-specific phospholipase C (PI-PLC). We report here that exposure of either bovine aortic EC, smooth muscle cells (SMC), or wild-type CHO cells to PI-PLC released HSPG involved in the conversion of thrombin to an adhesive molecule. The adhesion-promoting activity of the released HSPG was abolished following treatment with heparinase but not chondroitinase ABC. Incubation of thrombin with heparan sulfate-deficient CHO cells or cells that were pretreated with PI-PLC failed to induce its conversion to an adhesive molecule, indicating that glypican was playing a major role in this conversion. Moreover, affinity-purified glypican, but not syndecan or fibroglycan, elicited efficient conversion of plasmin-treated thrombin into an adhesive molecule. Antibodies raised against the RGD site in thrombin failed to interact with native thrombin, prothrombin, or the RGD site in other adhesive proteins such as vitronectin, fibrinogen, or fibronectin. Anti-thrombin-RGD antibodies which blocked the adhesion-promoting activity of thrombin were also capable of recognizing thrombin that was first incubated with a suboptimal concentration of plasm in in the presence of PI-PLC-released HSPG. Heparin, heparan sulfate, and PI-PLC-released HSPG had no effect on other cellular properties of thrombin such as receptor binding and growth-promoting activity. Altogether we have demonstrated that the heparin binding domain in thrombin plays a specific role in promoting thrombin adhesive properties and that membrane-associated glypican is likely to be the major physiological inducer of this property.
我们之前已经证明,凝血酶拥有一个活性但隐蔽的精氨酸-甘氨酸-天冬氨酸(RGD)位点,该位点一旦暴露,就会通过ανβ3整合素诱导内皮细胞(EC)黏附[Bar-Shavit等人(1991年):《细胞生物学杂志》112:335]。这是在细胞表面相关的硫酸乙酰肝素蛋白聚糖(HSPG)和极低浓度的纤溶酶存在的情况下实现的[Bar-Shavit等人(1993年):《细胞生物学杂志》123:1279]。一部分细胞表面相关的HSPG(磷脂酰肌醇蛋白聚糖)通过共价连接的糖基磷脂酰肌醇(PI)残基锚定,该残基可以通过用糖基-PI特异性磷脂酶C(PI-PLC)处理而释放。我们在此报告,将牛主动脉内皮细胞、平滑肌细胞(SMC)或野生型CHO细胞暴露于PI-PLC会释放参与凝血酶转化为黏附分子的HSPG。用肝素酶处理后,释放的HSPG的黏附促进活性被消除,但用软骨素酶ABC处理则没有。将凝血酶与缺乏硫酸乙酰肝素的CHO细胞或用PI-PLC预处理的细胞孵育未能诱导其转化为黏附分子,这表明磷脂酰肌醇蛋白聚糖在这种转化中起主要作用。此外,亲和纯化的磷脂酰肌醇蛋白聚糖,而不是多配体蛋白聚糖或纤连蛋白聚糖,能有效地将纤溶酶处理的凝血酶转化为黏附分子。针对凝血酶中RGD位点产生的抗体不能与天然凝血酶、凝血酶原或其他黏附蛋白(如玻连蛋白、纤维蛋白原或纤连蛋白)中的RGD位点相互作用。阻断凝血酶黏附促进活性的抗凝血酶-RGD抗体也能够识别首先在亚最佳浓度的纤溶酶存在下与PI-PLC释放的HSPG一起孵育的凝血酶。肝素硫酸乙酰肝素和PI-PLC释放的HSPG对凝血酶的其他细胞特性(如受体结合和生长促进活性)没有影响。总之,我们已经证明凝血酶中的肝素结合结构域在促进凝血酶黏附特性方面起特定作用,并且膜相关的磷脂酰肌醇蛋白聚糖可能是这种特性的主要生理诱导物。